Area seniors celebrate project milestones ahead of graduation
Today marks the culmination of a four-year journey for seniors at the Carthage Technical Center.
'I've just been really excited to do my own project, and now that I've been able to do I,t I'm hoping that some freshmen are able to ask the same questions and get the same hype that I did,' said Damien Pauley, Carthage senior – PLTW engineering.
'We've worked hard to come up with these products and the research behind it,' said Maggie Boyd, Carthage senior, PLTW biomedical
'They've put together what they've learned in the last four years. And what they've accumulated in math and science, Mr. Barr's physics class. And they've put it all together to solve this problem,' said Chad Campbell, PLTW engineering instructor.
These students are part of the Project Lead The Way pathways in the CTC which include biomedical and engineering.
'My project was the para park, which would help people with parallel parking. So what we did was we had a device that would hook into the tail hitch of a vehicle, and then that would lift up the backend of a vehicle. Pull up, you can easily lift the backend, put it down, and you're easily parallel parked,' said Pauley.
'I based my project off of people with auto-immune diseases and chronic illnesses that have restricted diets. So, I worked on a product that would help expand people's diets without increasing the negative effects,' said Boyd.
When asked how their project helped them prepare for their future, they had nothing but good things to say.
'I'm majoring in biomedical science next year. So, creating a product that relates to the science is always good for me,' said Boyd.
'Even if you're not going into engineering, it helps with problem solving and communication. Because you need to work with people the entirety of the course,' said Pauley.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
08-07-2025
- Yahoo
Young Minds Ooze with Curiosity at CTC's Slime Camp
KILLEEN, Texas (FOX 44) – Young learners at Central Texas College's College for Kids program got to explore the fun side of chemistry through hands-on, gooey experiments! The Slippery Slime Science Camp has recently wrapped up. Throughout the week, students mixed, stretched, and squished their way through a variety of slime recipes, all while discovering the science behind the mess. Campers learned how different ingredients interact, observing chemical reactions in action through colorful and creative projects! CTC says the camp also reinforces the importance of understanding basic chemical properties at an early age. Introducing students to scientific concepts in a fun and accessible way not only supports their academic growth, but builds curiosity and confidence in STEM learning. Hands-on learning experiences like this are key to helping students retain information, think critically, and develop problem-solving skills. CTC says its College for Kids offers a variety of engaging, educational summer classes for students of all interests through July 22. From science and technology to the arts, the program provides opportunities for hands-on learning in a fun, safe environment! Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
18-06-2025
- Yahoo
Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board
NEW YORK and PARIS, June 18, 2025 (GLOBE NEWSWIRE) -- Rarecells, Inc., a leader in liquid biopsy technology, is pleased to announce the appointment of Dr. Rita Shaknovich to its Scientific Advisory Board. Dr. Shaknovich brings over 20 years of leadership experience across private industry and academia. She has a distinguished track record of building high-performing teams, developing innovative diagnostic tests, establishing world-class laboratory environments, and advancing critical research in cancer biology, genomics, and Shaknovich currently serves as Chief Medical Officer at Agilent Technologies, where she oversees medical strategy and contributes to the development of innovative diagnostic solutions. Prior to joining Agilent, Dr. Shaknovich held senior leadership positions at GRAIL and Cancer Genetics, where she played pivotal roles in clinical and translational initiatives. She began her career in academic medicine, serving as Assistant Professor at Weill Cornell Medical College and Montefiore Medical Center (NY). "We are honored to welcome Dr. Shaknovich to our Scientific Advisory Board," said Dr. Patrizia Paterlini, CEO and Founder of Rarecells, Inc. "Her extensive expertise in molecular pathology and her commitment to advancing cancer diagnostics align perfectly with Rarecells' mission to revolutionize early cancer detection through innovative liquid biopsy technologies." Rarecells, Inc. is renowned for its ISET® (Isolation by SizE of Tumor cells) technology, a cutting-edge approach that enables the detection of circulating tumor cells (CTCs) and CTC-DNA in the bloodstream, facilitating early cancer diagnosis and monitoring. The addition of Dr. Shaknovich to the Scientific Advisory Board underscores the company's dedication to integrating top-tier scientific insights into its research and development efforts. "I am excited to join Rarecells' Scientific Advisory Board and contribute to their groundbreaking work in liquid biopsy," said Dr. Shaknovich. "Early detection is crucial in the fight against cancer, and I look forward to collaborating with the team to advance technologies that can significantly impact patient outcomes." About Rarecells, Inc. Rarecells, Inc. is a leading company in the development of innovative non-invasive tests for early cancer diagnosis based on the proprietary hypersensitive approaches of combined CTC-DNA, ctDNA molecular detection and AI-based Circulating Tumor Cells (CTCs) identification. Founded in 2012, the firm is headquartered in New York with offices and laboratories in New York and Paris. For more information, visit A photo accompanying this announcement is available at CONTACT: Contact: media@
Yahoo
17-06-2025
- Yahoo
Angle PLC - EACR 2025: Innovation in AR Expression Profiling
ANGLE presents new data at EACR 2025 Highlighting Innovation in Androgen Receptor EXPRESSION profiling Poster presentation highlights development of a novel CTC-based assay GUILDFORD, SURREY / / June 17, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the presentation of a poster at the European Association for Cancer Research (EACR) Congress, taking place in Lisbon, Portugal from 16-19 June 2025. The poster entitled 'Combined microfluidic isolation and immunofluorescence staining of circulating tumour cells for the assessment of Androgen Receptor expression in metastatic prostate cancer blood samples', is being presented during the Biomarkers in Tissue and Blood session on Tuesday 17 June 2025. This assay addresses a significant unmet need in prostate cancer. The androgen receptor (AR) plays a central role in driving disease growth and progression, and changes in AR can lead to resistance to current treatments and the development of advanced incurable disease known as metastatic castration-resistant prostate cancer (mCRPC). With at least 130 ongoing clinical studies and a projected AR inhibitor market value of US $9.8 billion by 2032, there is growing demand for assays that can monitor AR activity1. ANGLE has developed a new approach for repeatable assessment of AR expression in prostate cancer patients using the Parsortix system and ANGLE's AR immunofluorescence assay. The assay was tested on blood spiked with prostate cancer cells exposed to increasing AR drug concentrations. The results showed a clear, statistically significant reduction in AR expression as AR-drug concentration increased, from over 80% AR-positive cells in untreated samples to under 20% at the highest drug level. This demonstrates the assay's high sensitivity and highlights its potential utility for pharmacodynamic assessment, enabling customers to monitor treatment response in real-time. The assay was then validated in blood samples from 20 patients with mCRPC. 50% of patients were CTC-positive and all CTC-positive patients had AR-positive CTCs enabling the assessment of AR expression levels. CTC clusters, which are known to be up to 100 times more metastatic, were observed in 80% of CTC-positive patients. All CTCs detected were mesenchymal or undergoing EMT, highlighting the importance of using the marker-independent Parsortix system in this patient cohort. This work demonstrates how ANGLE's Portrait AR workflow enables sensitive, real-time monitoring of AR expression from a simple blood draw. The assay is now available as part of ANGLE's assay menu to support pharma customers with longitudinal biomarker assessment in AR-targeted clinical trials. The poster will be available on ANGLE's website from 20:00 on Tuesday 17 June: ANGLE Chief Scientific Officer, Karen Miller, commented:"This work underscores the value of ANGLE's Parsortix system for enabling detailed protein analysis directly in intact CTCs. The androgen receptor assay development programme has successfully been completed, and we are excited by its potential to repeatably monitor drug response and resistance in prostate cancer trials. Sharing this data at EACR reflects our ongoing commitment to advancing precision oncology with innovative, real-world solutions." 1. For further information: ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Research Use Only. Not for use in diagnostic procedures. For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays. Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product: The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: ANGLE plc View the original press release on ACCESS Newswire Sign in to access your portfolio
